<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00147498</url>
  </required_header>
  <id_info>
    <org_study_id>A3921019</org_study_id>
    <nct_id>NCT00147498</nct_id>
  </id_info>
  <brief_title>Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 Weeks</brief_title>
  <official_title>A Phase 2a, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Compare 3 Dose Levels Of CP-690,550 Versus Placebo, Administered Orally Twice Daily (BID) For 6 Weeks, In The Treatment Of The Signs And Symptoms Of Subjects With Active Rheumatoid Arthritis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study's objective is to compare the efficacy of 3 dose levels of oral CP-690,550
      monotherapy (5 mg, 15 mg, and 30 mg twice daily [BID]) versus placebo administered over 6
      weeks for the treatment of the signs and symptoms of subjects with active rheumatoid
      arthritis (RA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2005</start_date>
  <completion_date type="Actual">June 2006</completion_date>
  <primary_completion_date type="Actual">June 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 6</measure>
    <time_frame>Week 6</time_frame>
    <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joints count (TJC); &gt;= 20% improvement in swollen joints count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</measure>
    <time_frame>Week 1, 2, 4, and 8</time_frame>
    <description>ACR20 response: &gt;=20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</measure>
    <time_frame>Week 1, 2, 4, 6, and 8</time_frame>
    <description>ACR50 response: &gt;= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</measure>
    <time_frame>Week 1, 2, 4, 6, and 8</time_frame>
    <description>ACR70 response: &gt;= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve</measure>
    <time_frame>Baseline up to Week 6</time_frame>
    <description>ACR-n: calculated by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant's assessment of disease activity; participant's global assessment of pain; physician's assessment of disease activity; participant's assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the AUC of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tender Joints Count (TJC)</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Tender Joints Count (TJC) at Week 1, 2, 4, 6 and 8</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicated an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Swollen Joints Count (SJC)</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Swollen Joints Count (SJC) at Week 1, 2, 4, 6 and 8</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Global Assessment (PtGA) of Arthritis</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm = very well and 100 mm = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 1, 2, 4, 6 and 8</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Global Assessment of Arthritis</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Physician Global Assessment of Arthritis at Week 1, 2, 4, 6 and 8</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Arthritis Pain</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Patient Assessment of Arthritis Pain at Week 1, 2, 4, 6 and 8</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 1, 2, 4, 6 and 8</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-Reactive Protein (CRP)</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 100 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in C-Reactive Protein (CRP) at Week 1, 2, 4, 6 and 8</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 mg/L to 100 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Activity Score Using 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score ranging 0 to 9.4; higher scores indicated greater affectation due to disease activity. DAS 28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity and greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity, and less than (&lt;) 2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Disease Activity Score Using 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 6, and 8</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score ranging 0 to 9.4; higher scores indicated greater affectation due to disease activity. DAS 28-3 (CRP) &lt;=3.2 implied low disease activity and &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6 = remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)</measure>
    <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
    <description>Disease improvement was classified as good, moderate, and no change based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of &gt;1.2 and a present score of &lt;=3.2; none: an improvement of &lt;=0.6 or &gt;0.6 to &lt;=1.2 with a present score of &gt;5.1; remaining participants were classified as having moderate improvement. Scores of good and moderate were considered to have therapeutic response.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">264</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>5 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP 690,550 5 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>15 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CP 690,550 15 mg BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>30 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablets administered at a dose of 30 mg BID for 6 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Oral tablets administered at a dose of 5 mg BID for 6 weeks</description>
    <arm_group_label>5 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>Oral tablets administered at a dose of 15 mg BID for 6 weeks</description>
    <arm_group_label>15 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CP-690,550</intervention_name>
    <description>30 mg BID for 6 weeks</description>
    <arm_group_label>30 mg BID</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo tablets</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The subject has a history of inadequate response to at least 1, but no more than 4, of
             the following DMARDs: sulfasalazine, injectable gold, methotrexate, leflunomide,
             cyclosporine, or a thiopurine derivative (azathioprine or 6-mercaptopurine)

        Exclusion Criteria:

          -  Current Therapy With Any DMARD Or Biologic
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33173</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>New Port Richey</city>
        <state>Florida</state>
        <zip>34652</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ocala</city>
        <state>Florida</state>
        <zip>34474-7455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Port Richey</city>
        <state>Florida</state>
        <zip>34668</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52001-7313</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dubuque</city>
        <state>Iowa</state>
        <zip>52002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Concord</city>
        <state>New Hampshire</state>
        <zip>03301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Plainview</city>
        <state>New York</state>
        <zip>11803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hickory</city>
        <state>North Carolina</state>
        <zip>28602</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Ducansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Johnstown</city>
        <state>Pennsylvania</state>
        <zip>15904</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231-4496</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Everett</city>
        <state>Washington</state>
        <zip>98201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74043-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Goiânia</city>
        <state>GO</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Curitiba</city>
        <state>PR</state>
        <zip>80060-240</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>04230-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>São Paulo</city>
        <state>SP</state>
        <zip>05001-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T5M 0H4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8P 5P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Saint John's</city>
        <state>Newfoundland and Labrador</state>
        <zip>A1C 5B8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4V2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>10098</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Dresden</city>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Neubrandenburg</city>
        <zip>17033</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Wiesbaden</city>
        <zip>65191</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>México</city>
        <state>D.f.</state>
        <zip>06726</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Tlalpan Seccion 16</city>
        <state>DF</state>
        <zip>14000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Aguascalientes</city>
        <zip>20230</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>San Luis Potosí</city>
        <zip>78240</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 11</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Piestany</city>
        <zip>921 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Zilina</city>
        <zip>012 07</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>L´hospitalet de Llobregat</city>
        <state>Barcelona</state>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Guadalajara</city>
        <zip>19002</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Mexico</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Austria</country>
  </removed_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A3921019&amp;StudyName=Three%20Dose%20Levels%20of%20CP-690%2C550%20Monotherapy%20Versus%20Placebo%2C%20Administered%20Orally%20Twice%20Daily%20%28BID%29%20for%206%20Weeks</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 2, 2005</study_first_submitted>
  <study_first_submitted_qc>September 2, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 7, 2005</study_first_posted>
  <results_first_submitted>November 19, 2012</results_first_submitted>
  <results_first_submitted_qc>December 20, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 30, 2013</results_first_posted>
  <disposition_first_submitted>November 7, 2012</disposition_first_submitted>
  <disposition_first_submitted_qc>November 7, 2012</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">November 12, 2012</disposition_first_posted>
  <last_update_submitted>December 20, 2012</last_update_submitted>
  <last_update_submitted_qc>December 20, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>oral JAK inhibitor</keyword>
  <keyword>clinical trial</keyword>
  <keyword>joint diseases</keyword>
  <keyword>anti-Inflammatory agents</keyword>
  <keyword>rheumatic diseases</keyword>
  <keyword>DMARD</keyword>
  <keyword>Antirheumatic Agents</keyword>
  <keyword>Autoimmune Diseases</keyword>
  <keyword>Immune System Diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tofacitinib</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>CP 690,550 5 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="P2">
          <title>CP-690,550 15 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="P3">
          <title>CP-690,550 30 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="69"/>
                <participants group_id="P3" count="69"/>
                <participants group_id="P4" count="65"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="58"/>
                <participants group_id="P2" count="60"/>
                <participants group_id="P3" count="52"/>
                <participants group_id="P4" count="48"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="17"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Laboratory abnormality</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant defaulted</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>CP 690,550 5 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="B2">
          <title>CP-690,550 15 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="B3">
          <title>CP-690,550 30 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="61"/>
            <count group_id="B2" value="69"/>
            <count group_id="B3" value="69"/>
            <count group_id="B4" value="65"/>
            <count group_id="B5" value="264"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.9" spread="10.8"/>
                    <measurement group_id="B2" value="51.8" spread="13.0"/>
                    <measurement group_id="B3" value="51.1" spread="10.6"/>
                    <measurement group_id="B4" value="51.3" spread="12.1"/>
                    <measurement group_id="B5" value="50.6" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="55"/>
                    <measurement group_id="B5" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 6</title>
        <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joints count (TJC); &gt;= 20% improvement in swollen joints count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
        <time_frame>Week 6</time_frame>
        <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 6</title>
          <description>ACR20 response: greater than or equal to (&gt;=) 20 percent (%) improvement in tender joints count (TJC); &gt;= 20% improvement in swollen joints count (SJC); and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the Health Assessment Questionnaire [HAQ]); and C-Reactive Protein (CRP).</description>
          <population>Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study treatment.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.49"/>
                    <measurement group_id="O2" value="81.16"/>
                    <measurement group_id="O3" value="76.81"/>
                    <measurement group_id="O4" value="29.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</title>
        <description>ACR20 response: &gt;=20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Week 1, 2, 4, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing data were imputed using Last Observation Carried Forward (LOCF) at Week 1, 2, and 4. Here ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response</title>
          <description>ACR20 response: &gt;=20% improvement in TJC; &gt;= 20% improvement in SJC; and &gt;= 20% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing data were imputed using Last Observation Carried Forward (LOCF) at Week 1, 2, and 4. Here ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n=61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.87"/>
                    <measurement group_id="O2" value="43.48"/>
                    <measurement group_id="O3" value="56.52"/>
                    <measurement group_id="O4" value="12.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.82"/>
                    <measurement group_id="O2" value="71.01"/>
                    <measurement group_id="O3" value="68.12"/>
                    <measurement group_id="O4" value="20.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.93"/>
                    <measurement group_id="O2" value="75.36"/>
                    <measurement group_id="O3" value="75.36"/>
                    <measurement group_id="O4" value="30.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=56,56,51,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.00"/>
                    <measurement group_id="O2" value="66.07"/>
                    <measurement group_id="O3" value="70.59"/>
                    <measurement group_id="O4" value="28.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
        <description>ACR50 response: &gt;= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing data were imputed using Last Observation Carried Forward (LOCF) at Week 1, 2, 4, and 6. Here ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response</title>
          <description>ACR50 response: &gt;= 50% improvement in TJC or SJC and 50% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing data were imputed using Last Observation Carried Forward (LOCF) at Week 1, 2, 4, and 6. Here ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n= 61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.56"/>
                    <measurement group_id="O2" value="8.70"/>
                    <measurement group_id="O3" value="18.84"/>
                    <measurement group_id="O4" value="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n= 61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.84"/>
                    <measurement group_id="O2" value="23.19"/>
                    <measurement group_id="O3" value="28.99"/>
                    <measurement group_id="O4" value="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n= 61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.79"/>
                    <measurement group_id="O2" value="42.03"/>
                    <measurement group_id="O3" value="42.03"/>
                    <measurement group_id="O4" value="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n= 61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.79"/>
                    <measurement group_id="O2" value="53.62"/>
                    <measurement group_id="O3" value="50.72"/>
                    <measurement group_id="O4" value="6.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=56,56,51,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.86"/>
                    <measurement group_id="O2" value="30.36"/>
                    <measurement group_id="O3" value="45.10"/>
                    <measurement group_id="O4" value="13.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
        <description>ACR70 response: &gt;= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
        <time_frame>Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing data were imputed using Last Observation Carried Forward (LOCF) at Week 1, 2, 4, and 6. Here ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response</title>
          <description>ACR70 response: &gt;= 70% improvement in TJC or SJC and 70% improvement in at least 3 of 5 remaining ACR core measures: participant assessment of pain; participant global assessment of disease activity; physician global assessment of disease activity; self-assessed disability (disability index of the HAQ); and CRP.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Missing data were imputed using Last Observation Carried Forward (LOCF) at Week 1, 2, 4, and 6. Here ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="69"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1 (n= 61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64"/>
                    <measurement group_id="O2" value="4.35"/>
                    <measurement group_id="O3" value="4.35"/>
                    <measurement group_id="O4" value="0.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n= 61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.92"/>
                    <measurement group_id="O2" value="4.35"/>
                    <measurement group_id="O3" value="10.14"/>
                    <measurement group_id="O4" value="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n= 61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.84"/>
                    <measurement group_id="O2" value="17.39"/>
                    <measurement group_id="O3" value="21.74"/>
                    <measurement group_id="O4" value="1.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n= 61,69,69,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.11"/>
                    <measurement group_id="O2" value="21.74"/>
                    <measurement group_id="O3" value="27.54"/>
                    <measurement group_id="O4" value="3.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=56,56,51,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.93"/>
                    <measurement group_id="O2" value="14.29"/>
                    <measurement group_id="O3" value="27.45"/>
                    <measurement group_id="O4" value="8.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve</title>
        <description>ACR-n: calculated by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant’s assessment of disease activity; participant’s global assessment of pain; physician’s assessment of disease activity; participant’s assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the AUC of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.</description>
        <time_frame>Baseline up to Week 6</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Numeric Index of American College of Rheumatology Response (ACR-n) Curve</title>
          <description>ACR-n: calculated by taking the lowest percentage improvement in (1) SJC or (2) TJC or (3) the median of the remaining 5 components of the ACR response (participant’s assessment of disease activity; participant’s global assessment of pain; physician’s assessment of disease activity; participant’s assessment of physical function; an acute phase reactant value - CRP). Negative numbers indicate worsening. The area under the curve (AUC) for ACR-n is the measure of the AUC of the mean change from baseline in ACR-n. The trapezoidal rule was used to compute the AUC.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure.</population>
          <units>units on a scale*weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="857.50" spread="1151.36"/>
                    <measurement group_id="O2" value="1086.90" spread="1664.77"/>
                    <measurement group_id="O3" value="1211.93" spread="2107.65"/>
                    <measurement group_id="O4" value="-546.41" spread="1721.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tender Joints Count (TJC)</title>
        <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Tender Joints Count (TJC)</title>
          <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=61,69,68,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32.37" spread="1.588"/>
                    <measurement group_id="O2" value="26.98" spread="1.485"/>
                    <measurement group_id="O3" value="29.52" spread="1.499"/>
                    <measurement group_id="O4" value="30.61" spread="1.529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=60,68,66,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.49" spread="1.597"/>
                    <measurement group_id="O2" value="16.62" spread="1.492"/>
                    <measurement group_id="O3" value="15.75" spread="1.511"/>
                    <measurement group_id="O4" value="27.39" spread="1.576"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=57,66,65,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.90" spread="1.622"/>
                    <measurement group_id="O2" value="12.72" spread="1.505"/>
                    <measurement group_id="O3" value="13.51" spread="1.519"/>
                    <measurement group_id="O4" value="24.71" spread="1.572"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=56,58,59,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.33" spread="1.628"/>
                    <measurement group_id="O2" value="9.97" spread="1.562"/>
                    <measurement group_id="O3" value="10.17" spread="1.562"/>
                    <measurement group_id="O4" value="19.78" spread="1.670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=56,59,53,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.21" spread="1.630"/>
                    <measurement group_id="O2" value="8.58" spread="1.556"/>
                    <measurement group_id="O3" value="7.41" spread="1.612"/>
                    <measurement group_id="O4" value="19.81" spread="1.661"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=57,56,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.32" spread="1.62"/>
                    <measurement group_id="O2" value="11.50" spread="1.58"/>
                    <measurement group_id="O3" value="11.21" spread="1.62"/>
                    <measurement group_id="O4" value="20.37" spread="1.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Tender Joints Count (TJC) at Week 1, 2, 4, 6 and 8</title>
        <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicated an improvement.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joints Count (TJC) at Week 1, 2, 4, 6 and 8</title>
          <description>Number of tender joints was determined by examining 68 joints and identified the joints that were painful under pressure or to passive motion. The number of tender joints was recorded on the joint assessment form at each visit, no tenderness = 0, tenderness = 1. A negative value in change from baseline indicated an improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>tender joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1 (n=60,68,65,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.06" spread="1.435"/>
                    <measurement group_id="O2" value="-11.70" spread="1.338"/>
                    <measurement group_id="O3" value="-14.14" spread="1.362"/>
                    <measurement group_id="O4" value="-2.74" spread="1.417"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2 (n=57,66,65,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.68" spread="1.459"/>
                    <measurement group_id="O2" value="-15.66" spread="1.350"/>
                    <measurement group_id="O3" value="-15.78" spread="1.365"/>
                    <measurement group_id="O4" value="-5.13" spread="1.416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=56,58,58,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.23" spread="1.465"/>
                    <measurement group_id="O2" value="-18.33" spread="1.403"/>
                    <measurement group_id="O3" value="-18.66" spread="1.413"/>
                    <measurement group_id="O4" value="-10.09" spread="1.508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n=56,59,52,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.35" spread="1.466"/>
                    <measurement group_id="O2" value="-19.81" spread="1.398"/>
                    <measurement group_id="O3" value="-21.37" spread="1.461"/>
                    <measurement group_id="O4" value="-9.69" spread="1.500"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=57,56,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.26" spread="1.46"/>
                    <measurement group_id="O2" value="-16.89" spread="1.42"/>
                    <measurement group_id="O3" value="-17.78" spread="1.46"/>
                    <measurement group_id="O4" value="-9.34" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Swollen Joints Count (SJC)</title>
        <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Swollen Joints Count (SJC)</title>
          <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="65"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=61,69,68,65)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.33" spread="1.052"/>
                    <measurement group_id="O2" value="16.42" spread="0.984"/>
                    <measurement group_id="O3" value="19.53" spread="0.993"/>
                    <measurement group_id="O4" value="19.97" spread="1.013"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=60,68,66,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.77" spread="1.058"/>
                    <measurement group_id="O2" value="9.90" spread="0.989"/>
                    <measurement group_id="O3" value="10.18" spread="1.001"/>
                    <measurement group_id="O4" value="16.46" spread="1.044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=57,66,65,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.04" spread="1.074"/>
                    <measurement group_id="O2" value="6.84" spread="0.997"/>
                    <measurement group_id="O3" value="7.99" spread="1.006"/>
                    <measurement group_id="O4" value="14.30" spread="1.041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=56,58,59,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.83" spread="1.079"/>
                    <measurement group_id="O2" value="5.95" spread="1.035"/>
                    <measurement group_id="O3" value="6.42" spread="1.035"/>
                    <measurement group_id="O4" value="11.78" spread="1.107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=56,59,53,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.74" spread="1.080"/>
                    <measurement group_id="O2" value="4.93" spread="1.031"/>
                    <measurement group_id="O3" value="4.95" spread="1.069"/>
                    <measurement group_id="O4" value="11.15" spread="1.101"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=57,56,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.31" spread="1.07"/>
                    <measurement group_id="O2" value="6.02" spread="1.05"/>
                    <measurement group_id="O3" value="6.77" spread="1.08"/>
                    <measurement group_id="O4" value="12.36" spread="1.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Swollen Joints Count (SJC) at Week 1, 2, 4, 6 and 8</title>
        <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joints Count (SJC) at Week 1, 2, 4, 6 and 8</title>
          <description>Number of swollen joints was determined by examination of 66 joints and identifying when swelling was present. The number of swollen joints was recorded on the joint assessment form at each visit, no swelling = 0, swelling =1. A negative value in change from baseline indicates an improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>swollen joints</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="60"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1 (n=60,68,65,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.02" spread="0.913"/>
                    <measurement group_id="O2" value="-8.20" spread="0.855"/>
                    <measurement group_id="O3" value="-9.00" spread="0.866"/>
                    <measurement group_id="O4" value="-3.19" spread="0.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2 (n=57,66,65,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.83" spread="0.927"/>
                    <measurement group_id="O2" value="-11.33" spread="0.863"/>
                    <measurement group_id="O3" value="-11.11" spread="0.868"/>
                    <measurement group_id="O4" value="-5.23" spread="0.900"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=56,58,58,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.03" spread="0.930"/>
                    <measurement group_id="O2" value="-12.10" spread="0.894"/>
                    <measurement group_id="O3" value="-12.58" spread="0.897"/>
                    <measurement group_id="O4" value="-7.73" spread="0.954"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n=56,59,52,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.10" spread="0.931"/>
                    <measurement group_id="O2" value="-13.13" spread="0.891"/>
                    <measurement group_id="O3" value="-13.91" spread="0.925"/>
                    <measurement group_id="O4" value="-8.06" spread="0.950"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=57,56,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.54" spread="0.93"/>
                    <measurement group_id="O2" value="-12.02" spread="0.90"/>
                    <measurement group_id="O3" value="-12.14" spread="0.93"/>
                    <measurement group_id="O4" value="-7.00" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Global Assessment (PtGA) of Arthritis</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm = very well and 100 mm = very poorly.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Global Assessment (PtGA) of Arthritis</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 millimeter (mm) Visual Analog Scale (VAS) where 0 mm = very well and 100 mm = very poorly.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="58"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=57,67,65,63)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.03" spread="3.126"/>
                    <measurement group_id="O2" value="69.37" spread="2.887"/>
                    <measurement group_id="O3" value="63.99" spread="2.941"/>
                    <measurement group_id="O4" value="65.73" spread="2.985"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=58,67,64,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.89" spread="3.111"/>
                    <measurement group_id="O2" value="45.36" spread="2.889"/>
                    <measurement group_id="O3" value="39.79" spread="2.958"/>
                    <measurement group_id="O4" value="61.48" spread="3.076"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=55,65,62,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.18" spread="3.171"/>
                    <measurement group_id="O2" value="41.09" spread="2.917"/>
                    <measurement group_id="O3" value="32.09" spread="2.992"/>
                    <measurement group_id="O4" value="58.02" spread="3.046"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=56,58,58,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38.67" spread="3.146"/>
                    <measurement group_id="O2" value="29.53" spread="3.033"/>
                    <measurement group_id="O3" value="26.16" spread="3.062"/>
                    <measurement group_id="O4" value="52.55" spread="3.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=55,59,52,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.11" spread="3.165"/>
                    <measurement group_id="O2" value="28.82" spread="3.018"/>
                    <measurement group_id="O3" value="24.52" spread="3.180"/>
                    <measurement group_id="O4" value="50.04" spread="3.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=57,57,50,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.29" spread="3.13"/>
                    <measurement group_id="O2" value="37.56" spread="3.05"/>
                    <measurement group_id="O3" value="30.63" spread="3.23"/>
                    <measurement group_id="O4" value="50.76" spread="3.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 1, 2, 4, 6 and 8</title>
        <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Global Assessment (PtGA) of Arthritis at Week 1, 2, 4, 6 and 8</title>
          <description>Participants answered: &quot;Considering all the ways your arthritis affects you, how are you feeling today?&quot; Participants responded by using a 0 - 100 mm VAS, where 0 mm = very well and 100 mm = very poorly.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="66"/>
                <count group_id="O3" value="62"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1 (n=56,66,62,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.98" spread="3.121"/>
                    <measurement group_id="O2" value="-21.56" spread="2.859"/>
                    <measurement group_id="O3" value="-26.16" spread="2.948"/>
                    <measurement group_id="O4" value="-5.18" spread="3.022"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2 (n=53,63,60,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-22.06" spread="3.184"/>
                    <measurement group_id="O2" value="-25.71" spread="2.900"/>
                    <measurement group_id="O3" value="-33.33" spread="2.984"/>
                    <measurement group_id="O4" value="-8.14" spread="2.998"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=53,57,55,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-30.23" spread="3.176"/>
                    <measurement group_id="O2" value="-37.35" spread="3.001"/>
                    <measurement group_id="O3" value="-38.71" spread="3.072"/>
                    <measurement group_id="O4" value="-13.17" spread="3.238"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n=52,57,49,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.64" spread="3.203"/>
                    <measurement group_id="O2" value="-37.78" spread="3.005"/>
                    <measurement group_id="O3" value="-40.50" spread="3.191"/>
                    <measurement group_id="O4" value="-15.06" spread="3.219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=53,55,48,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-27.83" spread="3.18"/>
                    <measurement group_id="O2" value="-28.79" spread="3.04"/>
                    <measurement group_id="O3" value="-34.30" spread="3.21"/>
                    <measurement group_id="O4" value="-14.96" spread="3.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Physician Global Assessment of Arthritis</title>
        <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Physician Global Assessment of Arthritis</title>
          <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=60,69,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.39" spread="2.566"/>
                    <measurement group_id="O2" value="64.11" spread="2.388"/>
                    <measurement group_id="O3" value="66.65" spread="2.436"/>
                    <measurement group_id="O4" value="67.75" spread="2.471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=60,67,64,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.85" spread="2.568"/>
                    <measurement group_id="O2" value="37.80" spread="2.417"/>
                    <measurement group_id="O3" value="36.30" spread="2.464"/>
                    <measurement group_id="O4" value="55.54" spread="2.575"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=57,66,65,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.65" spread="2.618"/>
                    <measurement group_id="O2" value="29.54" spread="2.430"/>
                    <measurement group_id="O3" value="32.24" spread="2.453"/>
                    <measurement group_id="O4" value="52.76" spread="2.546"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=56,58,59,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.18" spread="2.631"/>
                    <measurement group_id="O2" value="27.45" spread="2.547"/>
                    <measurement group_id="O3" value="23.91" spread="2.540"/>
                    <measurement group_id="O4" value="46.01" spread="2.746"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=55,58,53,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.42" spread="2.651"/>
                    <measurement group_id="O2" value="22.22" spread="2.549"/>
                    <measurement group_id="O3" value="19.26" spread="2.643"/>
                    <measurement group_id="O4" value="46.52" spread="2.727"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=57,57,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.10" spread="2.62"/>
                    <measurement group_id="O2" value="30.78" spread="2.57"/>
                    <measurement group_id="O3" value="26.24" spread="2.66"/>
                    <measurement group_id="O4" value="42.04" spread="2.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Physician Global Assessment of Arthritis at Week 1, 2, 4, 6 and 8</title>
        <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Physician Global Assessment of Arthritis at Week 1, 2, 4, 6 and 8</title>
          <description>Physician Global Assessment of Arthritis was measured on a 0 to 100 mm VAS, where 0 mm = very good and 100 mm = very bad.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1 (n=59,67,62,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.13" spread="2.626"/>
                    <measurement group_id="O2" value="-28.25" spread="2.445"/>
                    <measurement group_id="O3" value="-30.89" spread="2.534"/>
                    <measurement group_id="O4" value="-12.25" spread="2.636"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2 (n=56,66,63,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.43" spread="2.675"/>
                    <measurement group_id="O2" value="-36.60" spread="2.456"/>
                    <measurement group_id="O3" value="-34.56" spread="2.525"/>
                    <measurement group_id="O4" value="-14.29" spread="2.611"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=55,58,56,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-33.29" spread="2.686"/>
                    <measurement group_id="O2" value="-38.44" spread="2.563"/>
                    <measurement group_id="O3" value="-42.65" spread="2.627"/>
                    <measurement group_id="O4" value="-20.91" spread="2.803"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n=55,58,50,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-35.97" spread="2.690"/>
                    <measurement group_id="O2" value="-43.69" spread="2.566"/>
                    <measurement group_id="O3" value="-46.70" spread="2.730"/>
                    <measurement group_id="O4" value="-19.87" spread="2.786"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=56,57,50,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.19" spread="2.67"/>
                    <measurement group_id="O2" value="-35.11" spread="2.58"/>
                    <measurement group_id="O3" value="-39.81" spread="2.73"/>
                    <measurement group_id="O4" value="-24.78" spread="2.87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Arthritis Pain</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Arthritis Pain</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="66"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=59,68,66,64)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.46" spread="3.112"/>
                    <measurement group_id="O2" value="67.47" spread="2.894"/>
                    <measurement group_id="O3" value="68.13" spread="2.936"/>
                    <measurement group_id="O4" value="64.17" spread="2.980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=59,68,65,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.76" spread="3.114"/>
                    <measurement group_id="O2" value="46.11" spread="2.897"/>
                    <measurement group_id="O3" value="37.71" spread="2.953"/>
                    <measurement group_id="O4" value="62.51" spread="3.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=57,65,65,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.59" spread="3.154"/>
                    <measurement group_id="O2" value="40.14" spread="2.940"/>
                    <measurement group_id="O3" value="30.83" spread="2.956"/>
                    <measurement group_id="O4" value="60.65" spread="3.062"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=57,58,59,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37.77" spread="3.150"/>
                    <measurement group_id="O2" value="30.42" spread="3.057"/>
                    <measurement group_id="O3" value="26.76" spread="3.053"/>
                    <measurement group_id="O4" value="56.96" spread="3.287"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=55,59,53,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.57" spread="3.191"/>
                    <measurement group_id="O2" value="28.35" spread="3.043"/>
                    <measurement group_id="O3" value="23.39" spread="3.169"/>
                    <measurement group_id="O4" value="52.75" spread="3.266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=57,57,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.44" spread="3.15"/>
                    <measurement group_id="O2" value="37.62" spread="3.08"/>
                    <measurement group_id="O3" value="31.12" spread="3.19"/>
                    <measurement group_id="O4" value="49.06" spread="3.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Patient Assessment of Arthritis Pain at Week 1, 2, 4, 6 and 8</title>
        <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Patient Assessment of Arthritis Pain at Week 1, 2, 4, 6 and 8</title>
          <description>Participants rated the severity of arthritis pain on a 0 to 100 mm VAS, where 0 mm = no pain and 100 mm = most severe pain.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mm</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="57"/>
                <count group_id="O2" value="67"/>
                <count group_id="O3" value="63"/>
                <count group_id="O4" value="59"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1 (n=57,67,63,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.01" spread="3.102"/>
                    <measurement group_id="O2" value="-19.74" spread="2.843"/>
                    <measurement group_id="O3" value="-29.66" spread="2.932"/>
                    <measurement group_id="O4" value="-3.30" spread="3.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2 (n=55,65,63,59)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-21.44" spread="3.142"/>
                    <measurement group_id="O2" value="-26.10" spread="2.870"/>
                    <measurement group_id="O3" value="-35.85" spread="2.936"/>
                    <measurement group_id="O4" value="-4.79" spread="3.027"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=55,57,56,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-29.27" spread="3.137"/>
                    <measurement group_id="O2" value="-35.47" spread="2.996"/>
                    <measurement group_id="O3" value="-40.10" spread="3.050"/>
                    <measurement group_id="O4" value="-8.40" spread="3.242"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n=54,58,51,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-31.42" spread="3.159"/>
                    <measurement group_id="O2" value="-37.67" spread="2.983"/>
                    <measurement group_id="O3" value="-42.89" spread="3.144"/>
                    <measurement group_id="O4" value="-12.26" spread="3.223"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=55,56,51,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-24.90" spread="3.14"/>
                    <measurement group_id="O2" value="-28.70" spread="3.02"/>
                    <measurement group_id="O3" value="-35.35" spread="3.15"/>
                    <measurement group_id="O4" value="-16.28" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Health Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="60"/>
                <count group_id="O2" value="69"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=60,69,67,62)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.75" spread="0.086"/>
                    <measurement group_id="O2" value="1.66" spread="0.080"/>
                    <measurement group_id="O3" value="1.61" spread="0.081"/>
                    <measurement group_id="O4" value="1.71" spread="0.083"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=60,68,65,58)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.46" spread="0.086"/>
                    <measurement group_id="O2" value="1.37" spread="0.080"/>
                    <measurement group_id="O3" value="1.19" spread="0.082"/>
                    <measurement group_id="O4" value="1.63" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=57,66,64,60)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.32" spread="0.087"/>
                    <measurement group_id="O2" value="1.17" spread="0.081"/>
                    <measurement group_id="O3" value="1.06" spread="0.082"/>
                    <measurement group_id="O4" value="1.53" spread="0.084"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=57,57,59,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.17" spread="0.087"/>
                    <measurement group_id="O2" value="1.07" spread="0.083"/>
                    <measurement group_id="O3" value="0.92" spread="0.083"/>
                    <measurement group_id="O4" value="1.54" spread="0.088"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=54,59,53,50)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="0.088"/>
                    <measurement group_id="O2" value="0.95" spread="0.082"/>
                    <measurement group_id="O3" value="0.86" spread="0.084"/>
                    <measurement group_id="O4" value="1.47" spread="0.087"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=57,56,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.30" spread="0.09"/>
                    <measurement group_id="O2" value="1.06" spread="0.08"/>
                    <measurement group_id="O3" value="0.92" spread="0.08"/>
                    <measurement group_id="O4" value="1.52" spread="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 1, 2, 4, 6 and 8</title>
        <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 1, 2, 4, 6 and 8</title>
          <description>HAQ-DI: participant-reported assessment of ability to perform tasks in 8 categories of daily living activities: dress/groom; arise; eat; walk; reach; grip; hygiene; and common activities over past week. Each item scored on 4-point scale from 0 to 3: 0=no difficulty; 1=some difficulty; 2=much difficulty; 3=unable to do. Overall score was computed as the sum of domain scores and divided by the number of domains answered. Total possible score range 0-3 where 0 = least difficulty and 3 = extreme difficulty.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="68"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="57"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1 (n=59,68,64,55)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.25" spread="0.066"/>
                    <measurement group_id="O2" value="-0.30" spread="0.061"/>
                    <measurement group_id="O3" value="-0.44" spread="0.063"/>
                    <measurement group_id="O4" value="-0.05" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2 (n=56,66,63,57)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.067"/>
                    <measurement group_id="O2" value="-0.50" spread="0.062"/>
                    <measurement group_id="O3" value="-0.56" spread="0.063"/>
                    <measurement group_id="O4" value="-0.15" spread="0.067"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=56,57,57,44)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.55" spread="0.067"/>
                    <measurement group_id="O2" value="-0.60" spread="0.064"/>
                    <measurement group_id="O3" value="-0.69" spread="0.065"/>
                    <measurement group_id="O4" value="-0.13" spread="0.071"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n=55,59,51,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.60" spread="0.068"/>
                    <measurement group_id="O2" value="-0.72" spread="0.063"/>
                    <measurement group_id="O3" value="-0.74" spread="0.067"/>
                    <measurement group_id="O4" value="-0.20" spread="0.070"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=56,56,51,43)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.43" spread="0.07"/>
                    <measurement group_id="O2" value="-0.60" spread="0.06"/>
                    <measurement group_id="O3" value="-0.70" spread="0.07"/>
                    <measurement group_id="O4" value="-0.17" spread="0.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>C-Reactive Protein (CRP)</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 100 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>C-Reactive Protein (CRP)</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 milligram per liter (mg/L) to 100 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="58"/>
                <count group_id="O4" value="53"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=50,57,58,53)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.25" spread="35.00"/>
                    <measurement group_id="O2" value="25.47" spread="31.06"/>
                    <measurement group_id="O3" value="28.10" spread="28.43"/>
                    <measurement group_id="O4" value="22.28" spread="18.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=50,55,55,49)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.98" spread="16.72"/>
                    <measurement group_id="O2" value="7.57" spread="9.79"/>
                    <measurement group_id="O3" value="7.57" spread="11.32"/>
                    <measurement group_id="O4" value="25.40" spread="30.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=46,53,53,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.18" spread="12.97"/>
                    <measurement group_id="O2" value="7.25" spread="11.83"/>
                    <measurement group_id="O3" value="6.50" spread="14.81"/>
                    <measurement group_id="O4" value="24.41" spread="21.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=46,49,47,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.83" spread="11.10"/>
                    <measurement group_id="O2" value="5.17" spread="6.72"/>
                    <measurement group_id="O3" value="5.88" spread="10.98"/>
                    <measurement group_id="O4" value="22.26" spread="21.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=45,49,41,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.57" spread="21.01"/>
                    <measurement group_id="O2" value="6.59" spread="16.37"/>
                    <measurement group_id="O3" value="6.08" spread="11.80"/>
                    <measurement group_id="O4" value="22.94" spread="20.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=45,45,41,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.37" spread="22.72"/>
                    <measurement group_id="O2" value="12.06" spread="12.20"/>
                    <measurement group_id="O3" value="13.95" spread="14.68"/>
                    <measurement group_id="O4" value="23.64" spread="29.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in C-Reactive Protein (CRP) at Week 1, 2, 4, 6 and 8</title>
        <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 mg/L to 100 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-Reactive Protein (CRP) at Week 1, 2, 4, 6 and 8</title>
          <description>The test for CRP is a laboratory measurement for evaluation of an acute phase reactant of inflammation through the use of an ultrasensitive assay. Normal range of CRP is 0 mg/L to 100 mg/L. A decrease in the level of CRP indicates reduction in inflammation and therefore improvement.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
                <count group_id="O4" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1 (n=50,54,55,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.28" spread="26.65"/>
                    <measurement group_id="O2" value="-18.29" spread="28.98"/>
                    <measurement group_id="O3" value="-21.38" spread="25.56"/>
                    <measurement group_id="O4" value="-0.24" spread="15.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2 (n=46,52,53,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.74" spread="32.94"/>
                    <measurement group_id="O2" value="-18.89" spread="31.87"/>
                    <measurement group_id="O3" value="-23.06" spread="31.49"/>
                    <measurement group_id="O4" value="1.79" spread="15.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=46,49,47,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.76" spread="33.31"/>
                    <measurement group_id="O2" value="-22.02" spread="31.29"/>
                    <measurement group_id="O3" value="-20.70" spread="25.69"/>
                    <measurement group_id="O4" value="-0.67" spread="19.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n=45,49,41,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-17.83" spread="35.92"/>
                    <measurement group_id="O2" value="-18.08" spread="25.99"/>
                    <measurement group_id="O3" value="-17.58" spread="24.76"/>
                    <measurement group_id="O4" value="0.67" spread="16.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=45,45,41,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.06" spread="35.75"/>
                    <measurement group_id="O2" value="-13.24" spread="27.69"/>
                    <measurement group_id="O3" value="-11.81" spread="29.46"/>
                    <measurement group_id="O4" value="1.32" spread="27.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Activity Score Using 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</title>
        <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score ranging 0 to 9.4; higher scores indicated greater affectation due to disease activity. DAS 28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity and greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity, and less than (&lt;) 2.6 = remission.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Activity Score Using 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP])</title>
          <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score ranging 0 to 9.4; higher scores indicated greater affectation due to disease activity. DAS 28-3 (CRP) less than or equal to (&lt;=) 3.2 implied low disease activity and greater than (&gt;) 3.2 to 5.1 implied moderate to high disease activity, and less than (&lt;) 2.6 = remission.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="57"/>
                <count group_id="O3" value="56"/>
                <count group_id="O4" value="51"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (n=50,57,56,51)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.17" spread="0.89"/>
                    <measurement group_id="O2" value="5.69" spread="0.92"/>
                    <measurement group_id="O3" value="5.91" spread="0.91"/>
                    <measurement group_id="O4" value="6.00" spread="0.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1 (n=49,54,54,47)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.29" spread="1.08"/>
                    <measurement group_id="O2" value="4.42" spread="1.12"/>
                    <measurement group_id="O3" value="4.28" spread="1.21"/>
                    <measurement group_id="O4" value="5.66" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2 (n=46,53,51,48)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.93" spread="1.08"/>
                    <measurement group_id="O2" value="3.80" spread="1.17"/>
                    <measurement group_id="O3" value="3.90" spread="1.17"/>
                    <measurement group_id="O4" value="5.37" spread="1.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4 (n=46,49,47,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.44" spread="1.20"/>
                    <measurement group_id="O2" value="3.56" spread="1.12"/>
                    <measurement group_id="O3" value="3.46" spread="1.33"/>
                    <measurement group_id="O4" value="4.91" spread="1.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6 (n=45,49,40,41)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.18" spread="1.29"/>
                    <measurement group_id="O2" value="3.42" spread="1.16"/>
                    <measurement group_id="O3" value="3.10" spread="1.17"/>
                    <measurement group_id="O4" value="4.78" spread="1.05"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8 (n=45,44,41,36)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.75" spread="1.37"/>
                    <measurement group_id="O2" value="4.08" spread="1.32"/>
                    <measurement group_id="O3" value="3.93" spread="1.38"/>
                    <measurement group_id="O4" value="5.02" spread="1.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Disease Activity Score Using 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 6, and 8</title>
        <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score ranging 0 to 9.4; higher scores indicated greater affectation due to disease activity. DAS 28-3 (CRP) &lt;=3.2 implied low disease activity and &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6 = remission.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all participants who were randomized to study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants who were evaluable for a particular time-point for each treatment arm, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score Using 28-Joints Count and C-Reactive Protein (3 Variables) (DAS28-3 [CRP]) at Week 1, 2, 4, 6, and 8</title>
          <description>DAS28-3 (CRP) was calculated from the SJC and TJC using the 28 joints count and CRP (mg/L). Total score ranging 0 to 9.4; higher scores indicated greater affectation due to disease activity. DAS 28-3 (CRP) &lt;=3.2 implied low disease activity and &gt;3.2 to 5.1 implied moderate to high disease activity, and &lt;2.6 = remission.</description>
          <population>FAS included all participants who were randomized to study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ signifies participants who were evaluable for a particular time-point for each treatment arm, respectively.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Change at Week 1 (n=49,53,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="0.74"/>
                    <measurement group_id="O2" value="-1.28" spread="0.99"/>
                    <measurement group_id="O3" value="-1.65" spread="0.99"/>
                    <measurement group_id="O4" value="-0.39" spread="0.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 2 (n=46,52,50,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.19" spread="0.89"/>
                    <measurement group_id="O2" value="-1.91" spread="1.23"/>
                    <measurement group_id="O3" value="-2.05" spread="1.25"/>
                    <measurement group_id="O4" value="-0.59" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 4 (n=46,49,46,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.64" spread="1.16"/>
                    <measurement group_id="O2" value="-2.18" spread="1.25"/>
                    <measurement group_id="O3" value="-2.47" spread="1.39"/>
                    <measurement group_id="O4" value="-1.04" spread="1.04"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 6 (n=45,49,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.99" spread="1.28"/>
                    <measurement group_id="O2" value="-2.28" spread="1.33"/>
                    <measurement group_id="O3" value="-2.73" spread="1.32"/>
                    <measurement group_id="O4" value="-1.20" spread="1.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change at Week 8 (n=45,44,41,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.36" spread="1.32"/>
                    <measurement group_id="O2" value="-1.60" spread="1.32"/>
                    <measurement group_id="O3" value="-1.99" spread="1.38"/>
                    <measurement group_id="O4" value="-0.89" spread="1.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)</title>
        <description>Disease improvement was classified as good, moderate, and no change based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of &gt;1.2 and a present score of &lt;=3.2; none: an improvement of &lt;=0.6 or &gt;0.6 to &lt;=1.2 with a present score of &gt;5.1; remaining participants were classified as having moderate improvement. Scores of good and moderate were considered to have therapeutic response.</description>
        <time_frame>Baseline, Week 1, 2, 4, 6, and 8</time_frame>
        <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
        <group_list>
          <group group_id="O1">
            <title>CP 690,550 5 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O2">
            <title>CP-690,550 15 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O3">
            <title>CP-690,550 30 mg</title>
            <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Categorization of Disease Improvement Based on DAS28-3 (CRP)</title>
          <description>Disease improvement was classified as good, moderate, and no change based on improvement in DAS 28-3 (CRP) from baseline and present DAS 28-3 (CRP) score. Good: an improvement from baseline of &gt;1.2 and a present score of &lt;=3.2; none: an improvement of &lt;=0.6 or &gt;0.6 to &lt;=1.2 with a present score of &gt;5.1; remaining participants were classified as having moderate improvement. Scores of good and moderate were considered to have therapeutic response.</description>
          <population>FAS included all randomized participants who received at least 1 dose of study treatment. Here ‘N’ (Number of Participants Analyzed) signifies participants who were evaluable for this measure and ‘n’ is number of participants evaluable at specific time points for each arm group, respectively.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="52"/>
                <count group_id="O4" value="46"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 1, No Change (n=49,53,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="25"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Good (n=49,53,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 1, Moderate (n=49,53,52,45)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="35"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, No Change (n=46,52,50,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Good (n=46,52,50,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 2, Moderate (n=46,52,50,46)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, No Change (n=46,49,46,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Good (n=46,49,46,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, Moderate (n=46,49,46,37)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="42"/>
                    <measurement group_id="O3" value="38"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6, No Change (n=45,49,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6, Good (n=45,49,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 6, Moderate (n=45,49,39,39)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="41"/>
                    <measurement group_id="O3" value="36"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, No Change (n=45,44,41,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Good (n=45,44,41,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, Moderate (n=45,44,41,35)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="28"/>
                    <measurement group_id="O3" value="30"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.</desc>
      <group_list>
        <group group_id="E1">
          <title>CP 690,550 5 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 5 milligram (mg) orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="E2">
          <title>CP-690,550 15 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 15 mg orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="E3">
          <title>CP-690,550 30 mg</title>
          <description>CP-690,550 tablets equivalent to CP-690,550 30 mg orally twice daily for 6 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Placebo matched to CP-690,550 tablets orally twice daily for 6 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pneumonia staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pyelonephritis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Whipple’s disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Syncope vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 9.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="37" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Cardiac disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Shoulder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="17" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pharyngolaryngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="65"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="61"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="65"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pfizer ClinicalTrials.gov Call Center</name_or_title>
      <organization>Pfizer, Inc.</organization>
      <phone>1-800-718-1021</phone>
      <email>ClinicalTrials.gov_Inquiries@pfizer.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

